Literature DB >> 31267496

Controlled Human Malaria Infection (CHMI) Studies: Over 100 Years of Experience with Parasite Injections.

Kai Matuschewski1, Steffen Borrmann2.   

Abstract

Human experimentation by deliberate infection with malarial parasites seems unethical yet has a long history in infectious disease research. After rigorous screening, volunteers are inoculated with Plasmodium sporozoites or blood stages and monitored under strict clinical supervision until they are treated with a licensed malaria drug and the infection is completely resolved. Historically, experimental Plasmodium challenge infections were applied to confirm that Anopheles mosquitoes were the malaria vector and to treat neurosyphilis in Treponema pallidum-infected patients. The lifesaving treatment with reliable parasite inoculation, monitoring, and drug cure was awarded with a Nobel Prize in 1927 and paved the way for human trials for clinical tests of candidate drugs and vaccines. Importantly, controlled human malaria infection (CHMI) studies are indispensable to bridge the major gap between phase I safety and phase II field trials. Here, we describe the biological basis, historical experiences, applications, and ethical considerations for CHMI studies. Acceleration of antimalarial drug and vaccine development remains a priority in medical research and critically depends on capacity building for CHMI studies.

Entities:  

Keywords:  Adverse effects; Asexual blood stage; Clinical monitoring; Drugs; Human trials; Malaria; Plasmodium; Sporozoite; Vaccines

Mesh:

Substances:

Year:  2019        PMID: 31267496     DOI: 10.1007/978-1-4939-9550-9_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  An Urgent Need for "Common Cold Units" to Study COVID-19.

Authors:  Scott B Halstead
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.

Authors:  Andrea Cox; Mark Sulkowski; Jeremy Sugarman
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 20.999

3.  COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.

Authors:  Scott B Halstead; Ramesh Akkina
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

4.  Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies.

Authors:  Adéla Nacer; Gaily Kivi; Raini Pert; Erkki Juronen; Pavlo Holenya; Eduardo Aliprandini; Rogerio Amino; Olivier Silvie; Doris Quinkert; Yann Le Duff; Matthew Hurley; Ulf Reimer; Andres Tover; Simon J Draper; Sarah Gilbert; Mei Mei Ho; Paul W Bowyer
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

Review 5.  Five decades of clinical assessment of whole-sporozoite malaria vaccines.

Authors:  Helena Nunes-Cabaço; Diana Moita; Miguel Prudêncio
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.